Treatment-focused Ebola trials, supportive care and future of filovirus care

References

• Kuhn JH. Guide to the correct use of filoviral nomenclature. Curr Top Microbiol Immunol. 2017 Jun 27. PubMed PMID: 28653188. DOI:10.1007/82_2017_7
   Google Scholar
• Brende B, Farrar J, Gashumba D, et al. CEPI-a new global R&D organisation for epidemic preparedness and response. Lancet. 2017 Jan 21;389(10066):233–235. PubMed PMID: 28109539.
   PubMed Web of Science ®Google Scholar
• Hayden EC. Unusual deal ensures Ebola vaccine supply. Nat News. 2016. DOI:10.1038/nature.2016.19186
   Google Scholar
• Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol Med. 2016 Feb;22(2):164–173. PubMed PMID: 26774636. DOI:10.1016/j.molmed.2015.12.005
   PubMed Web of Science ®Google Scholar
• Ohimain EI. Recent advances in the development of vaccines for Ebola virus disease. Virus Res. 2016 Jan 04;211:174–185. PubMed PMID: 26596227. DOI:10.1016/j.virusres.2015.10.021
   PubMed Web of Science ®Google Scholar
• Trad MA, Naughton W, Yeung A, et al. Ebola virus disease: an update on current prevention and management strategies. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2017 Jan;86:5–13. PubMed PMID: 27893999.
   PubMed Web of Science ®Google Scholar
• Cardile AP, Downey LG, Wiseman PD, et al. Antiviral therapeutics for the treatment of Ebola virus infection. Curr Opin Pharmacol. 2016 Oct;30:138–143. PubMed PMID: 27639220. DOI:10.1016/j.coph.2016.08.016
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Whaley KJ, Olinger GG, et al. Antibody therapeutics for Ebola virus disease. Curr Opin Virol. 2016 Apr;17:45–49. PubMed PMID: 26826442; PubMed Central PMCID: PMCPMC4902774.
   PubMed Web of Science ®Google Scholar
• Cardile AP, Warren TK, Martins KA, et al. Will there be a cure for Ebola? Annu Rev Pharmacol Toxicol. 2017 Jan 06; 57:329–348. PubMed PMID: 27959624. DOI:10.1146/annurev-pharmtox-010716-105055
   PubMed Web of Science ®Google Scholar
• Haque A, Hober D, Blondiaux J. Addressing therapeutic options for Ebola virus infection in current and future outbreaks. Antimicrob Agents Chemother. 2015 Oct;59(10):5892–5902. PubMed PMID: 26248374; PubMed Central PMCID: PMCPMC4576072. DOI:10.1128/AAC.01105-15
   PubMed Web of Science ®Google Scholar
• McMullan LK, Flint M, Dyall J, et al. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res. 2016 Jan;125:71–78. PubMed PMID: 26526586.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clinical Infectious Diseases. 2015 Sep 15;61(6):969–973. PubMed PMID: 25991468.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016 Jul 30;388(10043):498–503. PubMed PMID: 27209148; PubMed Central PMCID: PMCPMC4967715.
   PubMed Web of Science ®Google Scholar
• Dornemann J, Burzio C, Ronsse A, et al. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis. 2017 Jan 15;215(2):171–174. PubMed PMID: 28073857.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016 Mar 17;531(7594):381–385. PubMed PMID: 26934220; PubMed Central PMCID: PMCPMC5551389.
   PubMed Web of Science ®Google Scholar
• Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 2015 May 21;521(7552):362–365. PubMed PMID: 25901685; PubMed Central PMCID: PMCPMC4467030.
   PubMed Web of Science ®Google Scholar
• Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 2016 Apr;13(4:e1001997. PubMed PMID: 27093560; PubMed Central PMCID: PMCPMC4836798.
   Web of Science ®Google Scholar
• Sissoko D, Laouenan C, Folkesson E, et al. Correction: experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016 Apr;13(4:e1002009. PubMed PMID: 27046271; PubMed Central PMCID: PMCPMC4821578.
   Web of Science ®Google Scholar
• Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola Virus Disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016 Mar;13(3):e1001967. PubMed PMID: 26930627; PubMed Central PMCID: PMCPMC4773183 following competing interests: SB, XdL, HR, and SG received a grant from St Luke International University (Tokyo, Japan) to perform research on favipiravir in non-human primates. YY declared board membership for AbbVie, BMS, Gilead, MSD, Roche, Johnson&Johnson, ViiV Healthcare, Pfizer, and consultancy for AbbVie, BMS, Gilead, MSD, Roche, Johnson&Johnson, ViiV Healthcare, and Pfizer. OP worked for Fab’entech biotechnology from 1st April to 13th November 2015. Between January 2014 and now, SC received a grant from the CHU de Quebec research center, which had no relationship with the trial described in the paper. All other authors declared no conflict of interest.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014 Oct 02;514(7520):47–53. PubMed PMID: 25171469; PubMed Central PMCID: PMCPMC4214273.
   PubMed Web of Science ®Google Scholar
• Group Piw, Multi-National PIIST, Davey Rt, Jr., et al. A randomized, controlled trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016 Oct 13;375(15):1448–1456. PubMed PMID: 27732819; PubMed Central PMCID: PMCPMC5086427..
   PubMed Web of Science ®Google Scholar
• Konde MK, Baker DP, Traore FA, et al. Interferon beta-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PloS One. 2017;12(2):e0169255. PubMed PMID: 28225767; PubMed Central PMCID: PMCPMC5321269. DOI:10.1371/journal.pone.0169255
   PubMed Web of Science ®Google Scholar
• Van Griensven J, Edwards T, Baize S, et al. Efficacy of convalescent plasma in relation to dose of Ebola Virus Antibodies. N Engl J Med. 2016 Dec 08;375(23):2307–2309. PubMed PMID: 27959686.
   PubMed Web of Science ®Google Scholar
• Van Griensven J, Edwards T, De Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016 Jan 07;374(1):33–42. PubMed PMID: 26735992.
   PubMed Web of Science ®Google Scholar
• Dunning J, Kennedy SB, Antierens A, et al. Experimental treatment of Ebola virus disease with Brincidofovir. PloS One. 2016;11(9):e0162199. PubMed PMID: 27611077; PubMed Central PMCID: PMCPMC5017617 World Health Organization (WHO); the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the WHO. DOI:10.1371/journal.pone.0162199
   PubMed Web of Science ®Google Scholar
• Butler D. How to beat the next Ebola. Nature. 2015 Aug 06;524(7563):22–25. PubMed PMID: 26245563. DOI:10.1038/524022a
   PubMed Web of Science ®Google Scholar
• Colebunders RL, Cannon RO. Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease. J Infect Dis. 2015 Apr 15;211(8):1208–1210. PubMed PMID: 25635120. DOI:10.1093/infdis/jiv043
   PubMed Web of Science ®Google Scholar
• Burnouf T, Dye JM, Abayomi A, et al. Convalescent plasma and the dose of Ebola virus antibodies. N Engl J Med. 2017 Mar 30;376(13):1296–1297. PubMed PMID: 28355506.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Luczkowiak J, Delgado R. Convalescent plasma for Ebola virus disease. N Engl J Med. 2016 Jun 23;374(25):2498–2499. PubMed PMID: 27332914. DOI:10.1056/NEJMc1602284#SA1
   PubMedGoogle Scholar
• Luczkowiak J, Arribas JR, Gomez S, et al. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Res. 2016 Feb ;02(213):224–229. PubMed PMID: 26739425. DOI:10.1016/j.virusres.2015.12.019
   PubMed Web of Science ®Google Scholar
• Indolfi G, Thorne C, El Sayed MH, et al. The challenge of treating children with hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):851–854. PubMed PMID: 28362694.
   PubMed Web of Science ®Google Scholar
• Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May;33(3):115–119. PubMed PMID: 28350558. DOI:10.1097/MOG.0000000000000350
   PubMed Web of Science ®Google Scholar
• Schwarz TM, Edwards MR, Diederichs A, et al. VP24-karyopherin alpha binding affinities differ between Ebolavirus species, influencing interferon inhibition and VP24 Stability. J Virol. 2017 Feb 15;91(4). PubMed PMID: 27974555; PubMed Central PMCID: PMCPMC5286879. DOI:10.1128/JVI.01715-16
   Web of Science ®Google Scholar
• McCarthy SD, Majchrzak-Kita B, Racine T, et al. A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola Virus. PLoS Negl Trop Dis. 2016 Jan;10(1:e0004364. PubMed PMID: 26752302; PubMed Central PMCID: PMCPMC4709101.
   Web of Science ®Google Scholar
• Dunham EC, Banadyga L, Groseth A, et al. Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses. Nat Commun. 2015 Aug;05(6):8000. PubMed PMID: 26242723; PubMed Central PMCID: PMCPMC4527089. DOI:10.1038/ncomms9000
   PubMed Web of Science ®Google Scholar
• Audet J, Kobinger GP. Immune evasion in Ebolavirus infections. Viral Immunol. 2015 Feb;28(1):10–18. PubMed PMID: 25396298. DOI:10.1089/vim.2014.0066
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005 Dec;27(6):423–431. PubMed PMID: 16341948.
   PubMedGoogle Scholar
• Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 Feb;11(2:e0005389. PubMed PMID: 28231247; PubMed Central PMCID: PMCPMC5340401.
   Web of Science ®Google Scholar
• Bai CQ, Mu JS, Kargbo D, et al. Clinical and Virological Characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clinical Infectious Diseases. 2016 Nov 15;63(10):1288–1294. PubMed PMID: 27553371.
   PubMed Web of Science ®Google Scholar
• Uyeki T, editor. Ebola Therapeutics Overview. Rockville, MD: Filovirus Animal Model NonClinical Group Workshop; 2017. May 16.
   Google Scholar
• Bhiman JN, Lynch RM. Broadly neutralizing antibodies as treatment: effects on virus and immune system. Curr HIV/AIDS Rep. 2017 Apr;14(2):54–62. PubMed PMID: 28349376; PubMed Central PMCID: PMCPMC5401706. DOI:10.1007/s11904-017-0352-1
   PubMed Web of Science ®Google Scholar
• Blaszczak W, Barczak W, Wegner A, et al. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. Med Oncol. 2017 Apr;34(4):60. PubMed PMID: 28315228; PubMed Central PMCID: PMCPMC5357244.
   PubMed Web of Science ®Google Scholar
• Blinkenberg M, Soelberg Sorensen P. Monoclonal antibodies for relapsing multiple sclerosis: a review of recently marketed and late-stage agents. CNS Drugs. 2017 May;31(5):357–371. PubMed PMID: 28285378. DOI:10.1007/s40263-017-0414-3
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gonzalez E, Alvarez MM, Marquez-Ipina AR, et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol. 2017 Feb;37(1):53–68. PubMed PMID: 26611830.
   PubMed Web of Science ®Google Scholar
• Hiatt A, Pauly M, Whaley K, et al. The emergence of antibody therapies for Ebola. Hum Antibodies. 2015 Dec 23;23(3–4):49–56. PubMed PMID: 27472862.
   PubMedGoogle Scholar
• Uyeki TM, Mehta AK, Davey RT Jr., et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016 Feb 18;374(7):636–646. PubMed PMID: 26886522; PubMed Central PMCID: PMCPMC4972324.
   PubMed Web of Science ®Google Scholar
• McCarthy M. Ebola diagnosed in doctor in New York City. Bmj. 2014 Oct 24;349:g6453. doi: 10.1136/bmj.g6453. PubMed PMID: 25343951.
   PubMedGoogle Scholar
• Liddell AM, Davey RT, Jr., Mehta AK, et al. Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. Ann Intern Med. 2015 Jul 21;163(2):81–90. doi: 10.7326/M15-0530. PubMed PMID: 25961438; PubMed Central PMCID: PMCPMC4724427.
   PubMed Web of Science ®Google Scholar
• Kraft CS, Hewlett AL, Koepsell S, et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Aug 15;61(4):496–502. doi: 10.1093/cid/civ334. PubMed PMID: 25904375; PubMed Central PMCID: PMCPMC4542597.
   PubMed Web of Science ®Google Scholar
• Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. The New England journal of medicine. 2014 Dec 18;371(25):2402–9. doi: 10.1056/NEJMoa1409838. PubMed PMID: 25390460.
   PubMed Web of Science ®Google Scholar
• Leligdowicz A, Fischer WA, 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016 Jul 29;20(1):217. doi: 10.1186/s13054-016-1325-2. PubMed PMID: 27468829; PubMed Central PMCID: PMCPMC4965892.
   PubMedGoogle Scholar
• Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. The New England journal of medicine. 2015 Jun 18;372(25):2423–7. doi: 10.1056/NEJMoa1500306. PubMed PMID: 25950269; PubMed Central PMCID: PMCPMC4547451.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Aarons E, Bhagani S, et al. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis. 2015 Nov;15(11):1300–4. doi: 10.1016/S1473-3099(15)00228-5. PubMed PMID: 26321189.
   PubMed Web of Science ®Google Scholar
• Roddy P, Colebunders R, Jeffs B, et al. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. The Journal of infectious diseases. 2011 Nov;204 Suppl 3:S791–5. doi: 10.1093/infdis/jir297. PubMed PMID: 21987752.
   PubMedGoogle Scholar
• Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015 Nov;15(11):1292–9. doi: 10.1016/S1473-3099(15)00144-9. PubMed PMID: 26271406.
   PubMed Web of Science ®Google Scholar
• Marion D, Charlebois PB, Kao R. The healthcare workers’ clinical skill set requirements for a uniformed international response to the Ebola virus disease outbreak in West Africa: the Canadian perspective. J R Army Med Corps. 2016 Jun;162(3):207–11. doi: 10.1136/jramc-2015-000605. PubMed PMID: 26987351.
   PubMed Web of Science ®Google Scholar
• WHO. Clinical management of patients with viral haemorrhagic fever: A pocket guide for the front-line health worker. Geneva, Switzerland: WHO Press. 2016 Feb 2016.
   Google Scholar
• Canada PHAo. Canadian Ebola Clinical Care guideline. 2014. Available from: http://caep.ca/sites/caep.ca/files/caep/Endorsements/ebola_clinical_care_guideline_english_201505.pdf
   Google Scholar
• Sterk E. Filovirus Haemorrhagic Fever Guidelines. In: Frontières MS, editor. Barcelona, Spain: Médecins Sans Frontières (MSF). 2008.
   Google Scholar
• Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Critical care medicine. 2004 Mar;32(3):858–73. PubMed PMID: 15090974.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008 Jan;34(1):17–60. doi: 10.1007/s00134-007-0934-2. PubMed PMID: 18058085; PubMed Central PMCID: PMCPMC2249616.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013 Feb;39(2):165–228. doi: 10.1007/s00134-012-2769-8. PubMed PMID: 23361625.
   Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical care medicine. 2003 Apr;31(4):1250–6. doi: 10.1097/01.CCM.0000050454.01978.3B. PubMed PMID: 12682500.
   Google Scholar
• Singhi S, Chaudhary D, Varghese GM, et al. From: The Indian society of critical care medicine tropical fever group. Tropical fevers: management guidelines. Indian J Crit Care Med. 2014 Feb;18(2):62–9. doi: 10.4103/0972-5229.126074. PubMed PMID: 24678147; PubMed Central PMCID: PMCPMC3943129.
   PubMedGoogle Scholar
• Crump JA, Gove S, Parry CM. Management of adolescents and adults with febrile illness in resource limited areas. Bmj. 2011 Aug 08;343:d4847. doi: 10.1136/bmj.d4847. PubMed PMID: 21824901; PubMed Central PMCID: PMCPMC3164889.
   Google Scholar
• (TDR) WHOWatSPfRaTiTD. Dengue: Guidelines for diagnosis, treatment, prevention and control. France: WHO Press; 2009.
   Google Scholar
• Control CfD. Outbreaks Chronology: Marburg Hemorrhagic Fever 2014. [ cited 2017 Dec 6] Available from: https://www.cdc.gov/vhf/marburg/outbreaks/chronology.html
   Google Scholar
• Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. The Journal of infectious diseases. 1999 Feb;179 Suppl 1:S18–23. doi: 10.1086/514298. PubMed PMID: 9988160.
   PubMedGoogle Scholar
• Control CfD. Outbreaks Chronology: Ebola Virus Disease 2017. [ cited 2017 Dec 6] Available from: https://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
   Google Scholar
• Borchert M, Mutyaba I, Van Kerkhove MD, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis. 2011 Dec 28;11:357. doi: 10.1186/1471-2334-11-357. PubMed PMID: 22204600; PubMed Central PMCID: PMCPMC3276451.
   PubMed Web of Science ®Google Scholar
• Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. The New England journal of medicine. 2015 Jan 01;372(1):40–7. doi: 10.1056/NEJMoa1411249. PubMed PMID: 25372658.
   PubMed Web of Science ®Google Scholar
• Parra JM, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. The New England journal of medicine. 2014 Dec 18;371(25):2439–40. doi: 10.1056/NEJMc1412662. PubMed PMID: 25409262.
   PubMed Web of Science ®Google Scholar
• Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. The New England journal of medicine. 2014 Nov 27;371(22):2092–100. doi: 10.1056/NEJMoa1411680. PubMed PMID: 25353969; PubMed Central PMCID: PMCPMC4318555.
   PubMed Web of Science ®Google Scholar
• Kateh F, Nagbe T, Kieta A, et al. Rapid response to Ebola outbreaks in remote areas - Liberia, July-November 2014. MMWR Morb Mortal Wkly Rep. 2015 Feb 27;64(7):188–92. PubMed PMID: 25719682.
   PubMed Web of Science ®Google Scholar
• Ansumana R, Jacobsen KH, Sahr F, et al. Ebola in Freetown area, Sierra Leone--a case study of 581 patients. The New England journal of medicine. 2015 Feb 05;372(6):587–8. doi: 10.1056/NEJMc1413685. PubMed PMID: 25539447.
   PubMed Web of Science ®Google Scholar
• Lamontagne F, Fowler RA, Adhikari NK, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2017 Oct 17. doi: 10.1016/S0140-6736(17)31795-6. PubMed PMID: 29054555.
   PubMedGoogle Scholar
• Petersen E, Maiga B. Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed. Int J Infect Dis. 2015 Jan;30:85–6. doi: 10.1016/j.ijid.2014.12.002. PubMed PMID: 25481049.
   Google Scholar
• Oestereich L, Rieger T, Neumann M, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS neglected tropical diseases. 2014 May;8(5):e2804. doi: 10.1371/journal.pntd.0002804. PubMed PMID: 24786461; PubMed Central PMCID: PMCPMC4006714.
   Web of Science ®Google Scholar
• Caroline AL, Powell DS, Bethel LM, et al. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS neglected tropical diseases. 2014 Apr;8(4):e2790. doi: 10.1371/journal.pntd.0002790. PubMed PMID: 24722586; PubMed Central PMCID: PMCPMC3983105.
   Web of Science ®Google Scholar
• Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial agents and chemotherapy. 2009 Jan;53(1):202–9. doi: 10.1128/AAC.01074-08. PubMed PMID: 18955536; PubMed Central PMCID: PMCPMC2612161.
   PubMed Web of Science ®Google Scholar
• Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Scientific reports. 2017 Mar 06;7:43395. doi: 10.1038/srep43395. PubMed PMID: 28262699; PubMed Central PMCID: PMCPMC5338263.
   Google Scholar
• Upadhyay DK, Sittig DF, Singh H. Ebola US Patient Zero: lessons on misdiagnosis and effective use of electronic health records. Diagnosis (Berl). Diagnosis (Berl). 2014;1 (4):283.Epub 2014 Oct 23. doi: 10.1515/dx-2014-0064. PubMed PMID: 26705511. PubMed Central PMCID: PMC4687403.
   Google Scholar
• Spencer C. Having and fighting Ebola--public health lessons from a clinician turned patient. N Engl J Med. 2015 Mar 19;372(12):1089–91. doi: 10.1056/NEJMp1501355. PubMed PMID: 25714039.
   PubMed Web of Science ®Google Scholar
• Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med. 2015 Jul;3( 7):554–62. doi: 10.1016/S2213-2600(15)00180-0. PubMed PMID: 26041403.
   PubMed Web of Science ®Google Scholar
• Schibler M, Vetter P, Cherpillod P et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015 Sep;15(9):1034–1040. doi: 10.1016/S1473-3099(15)00229-7. PubMed PMID: 26201298.
   PubMed Web of Science ®Google Scholar
• Wolf T, Kann G, Becker S et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015 Apr 11;385(9976):1428–35. doi: 10.1016/S0140-6736(14)62384-9. PMID: 25534190.
   PubMed Web of Science ®Google Scholar